コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 sma membrane of adipocytes is a key facet of insulin action.
2 FoxO proteins are major targets of insulin action.
3 forms (IRB and IRA) that are responsible for insulin action.
4 and muscle tissues) and is rate limiting in insulin action.
5 s increasing and systemic effects decreasing insulin action.
6 delivery and largely independent of hepatic insulin action.
7 tributes to exercise-induced improvements in insulin action.
8 normal function of white adipose tissue and insulin action.
9 es that the brain is an important target for insulin action.
10 s proliferation is not required for enhanced insulin action.
11 oviding a novel target for the modulation of insulin action.
12 mpairs GSIS in HF-fed mice without affecting insulin action.
13 nto lipoproteins may improve skeletal muscle insulin action.
14 -cells in islets of Langerhans, and improves insulin action.
15 nadir, or mean of the normal periodicity of insulin action.
16 tricularly mediated blockade of hypothalamic insulin action.
17 atic ATGL on mediating glucose tolerance and insulin action.
18 rn-style diet (WSD) impairs offspring muscle insulin action.
19 ytokine as both an enhancer and inhibitor of insulin action.
20 -chain fatty acid oxidation disrupts hepatic insulin action.
21 substantially impairs glucose tolerance and insulin action.
22 taining the balance between inflammation and insulin action.
23 hesis of lipotoxic ceramides that antagonize insulin action.
24 umulation yet paradoxically improves hepatic insulin action.
25 s related to reduced insulin sensitivity and insulin action.
26 4 to cell cortex landing zones important for insulin action.
27 of rictor and mTOR, thereby down-regulating insulin action.
28 ycerol, ceramide, and acylcarnitine, disrupt insulin action.
29 ole in regulating hepatic and adipose tissue insulin action.
30 nd is critical for maintenance of whole body insulin action.
31 g with assessment of substrate selection and insulin action.
32 and suggest a more complex role for DAGs in insulin action.
33 eta-cell proliferation and if they influence insulin action.
34 ons, including modulation of skeletal muscle insulin action.
35 le-body metabolism via modulation of hepatic insulin action.
36 ype 2 diabetes results from an impairment of insulin action.
37 sed by insulin and thus are key mediators of insulin action.
38 from the hemolymph, a hallmark of bona fide insulin action.
39 ciates with both IR and IRS-1 and influences insulin action.
40 of TXNIP, a well-known negative regulator of insulin action.
41 ved in vivo monitoring of glucocorticoid and insulin action.
42 ons in regulating hepatic and adipose tissue insulin action.
43 s by altering either hepatic or extrahepatic insulin action.
44 cts increased, consistent with physiological insulin actions.
48 gs identify GPR55 as a positive regulator of insulin action and adipogenesis and as a potential thera
50 involved in the pathogenesis of T2DM, namely insulin action and beta cell function, and is considered
51 y mediates an early transient hepato-centric insulin action and blunts hypoglycaemia in dogs in respo
52 ence beta-cell physiology through regulating insulin action and demonstrated the therapeutic potentia
53 rous documentation for a circadian rhythm of insulin action and demonstrates that disturbing the natu
56 -induced visceral obesity but also regulates insulin action and glucose homeostasis, independently of
60 type 2 diabetes is characterized by impaired insulin action and increased hepatic glucose production
61 Conversely, Ctrp6 gene deletion improved insulin action and increased metabolic rate and energy e
62 and LRP5 activity can serve as modifiers of insulin action and insulin resistance in the pathophysio
63 TRA6 is necessary for diurnal rhythmicity of insulin action and JAK/STAT signaling in adipose tissue.
64 -knockout mice are locked into the trough of insulin action and lack rhythmicity in insulin action an
65 hereas its muscle-specific ablation impaired insulin action and led to postprandial glucose intoleran
67 ivity have the potential to improve systemic insulin action and limit weight gain on an obesigenic di
68 nction declines with aging, which can reduce insulin action and may contribute to increased risk of t
70 /lysosomal trafficking system may coordinate insulin action and nutrient homeostasis by endocytosis o
72 for compounds that enhance and partly mimic insulin action and replicate some effects of bariatric s
73 eveal a new role of MAM integrity in hepatic insulin action and resistance, providing a novel target
74 ented exercise training increased whole-body insulin action and reversed impairments in AS160 phospho
77 exercise training could rescue decrements in insulin action and skeletal muscle AS160 phosphorylation
78 otubes of severely obese individuals enhance insulin action and stimulate exercise-responsive molecul
79 muscle is a critical regulator of leptin and insulin action and that increased SOCS may mediate insul
83 d risk for diabetes decreased in response to insulin action and were elevated in the setting of insul
84 via the portal vein is important for hepatic insulin action and, therefore, presumably for hepatic in
88 -cell function and beta-cell mass, normalise insulin action, and fully correct glucose homoeostasis a
89 presence of altered eNOS activation, reduced insulin action, and inflammatory activation in the endot
91 apid mobilization of nutrient stores, impair insulin action, and ultimately cause hyperglycemia, a co
92 uscle causes an increase, not a decrease, in insulin action; and 3) most of the studies comparing fat
93 bnormalities in hepatic lipid metabolism and insulin action are believed to play a critical role in t
95 findings indicate that localized changes in insulin action are responsible for the differential phos
98 glucose uptake was independent of defects in insulin action at the myocyte, suggesting that the impai
100 and muscle-specific glucose homeostasis and insulin action based on glucose and insulin tolerance te
101 rons (AgRP IR KO) exhibited impaired hepatic insulin action because the ability of insulin to suppres
102 cription factor, is an important mediator of insulin action, but its role in the regulation of lipid
104 xK1 and FoxK2 are also downstream targets of insulin action, but that following insulin stimulation,
105 e training intervention increased whole-body insulin action by 26% and insulin-stimulated leg glucose
107 phatase 1B (PTP1B) is postulated to modulate insulin action by dephosphorylating the insulin receptor
108 GLP-1 may afford potential to improve muscle insulin action by expanding microvascular endothelial su
109 sia dracunculus L. (termed PMI5011) improves insulin action by increasing insulin signaling in skelet
111 that pharmacological FFA reduction enhances insulin action by reducing local (muscle) inflammation,
112 ose significantly enhances the assessment of insulin action by segregating insulin sensitivity into i
114 ce became markedly obese but showed improved insulin action compared to that of wild-type mice, which
117 dipocytes on myocyte substrate selection and insulin action depended on the metabolic state of the sy
118 t of a single bout of exercise on whole-body insulin action depends on the balance between local effe
121 Nevertheless, inhibition of hypothalamic insulin action did not alter the effects of the hormone
124 tween the metabolomic amino acid profile and insulin action (i.e., glucose disposal rate [GDR]).
125 e recently demonstrated a diurnal pattern to insulin action (i.e., insulin sensitivity [SI]) in healt
126 tion on parameters of glucose metabolism and insulin action in a dietary mouse model of obesity.
127 icial effects of 5-PAHSA and its relation to insulin action in adipocytes and independently confirm a
134 during hyperinsulinemia, suggesting impaired insulin action in adipose tissue, whereas no association
139 l amount of dietary LCFAs with MCFAs rescues insulin action in conditions of lipid-induced energy exc
141 e that in addition to prosurvival signaling, insulin action in early life mediates the physiological
143 , and phosphatidic acid (PA), which inhibits insulin action in hepatocytes by disrupting the assembly
144 generation of nitric oxide (NO) that impairs insulin action in hepatocytes via tyrosine nitration of
149 w that hepatic ILK deletion has no effect on insulin action in lean mice but sensitizes the liver to
150 duction and inflammation and enhances tissue insulin action in lean rats and 2) prevents muscle metab
151 perinsulinemic-euglycemic clamps, we studied insulin action in Liv-DGAT2 mice and their wild-type (WT
155 calcium deposition in the vasculature and of insulin action in muscle and fat, and may be involved in
158 172) phosphorylation, PGC1alpha content, and insulin action in myotubes of both the lean and severely
159 the exercise day, suggesting that decreased insulin action in nonexercised muscle may reduce GLUT4 t
160 tment has weight loss-independent effects on insulin action in obese subjects with type 2 diabetes.
161 ncy, but it is not known whether it improves insulin action in people who are not leptin deficient.
162 ulates the kinetics of insulin signaling and insulin action in peripheral target tissues and differen
165 lle contacts by overexpressing CypD enhanced insulin action in primary hepatocytes of diabetic mice.
166 e that can alter insulin clearance and hence insulin action in response to blood glucose, mitigating
167 d whole-body insulin action, suggesting that insulin action in rested muscle or other organs may be d
171 mportant regulator of lipid partitioning and insulin action in skeletal muscle under conditions of in
176 e in insulin sensitivity, including impaired insulin action in suppressing lipolysis and lipid oxidat
180 about the overall physiological relevance of insulin action in the brain on hepatic glucose metabolis
181 Together, dietary intake of MUFAs promoted insulin action in the brain with its beneficial effects
182 ects have been postulated to be mediated via insulin action in the brain, although peripheral effects
184 the coordination of fatty acid oxidation and insulin action in the fasting-refeeding transition.
186 erglycemia in diabetic mice independently of insulin action in the liver by increasing energy metabol
190 r intestinal tumour cells in vitro, impaired insulin action in the tumour microenvironment may be mor
191 tablish a novel role for PTP1B in regulating insulin action in the VMH and suggest that increased ins
192 mary human skeletal muscle myotubes improved insulin action in tissue from both lean and severely obe
198 est that the impaired increase in whole-body insulin action in women with PCOS with training is cause
199 ovides evidence to support the importance of insulin actions in preventing cardiovascular pathology t
200 e regulation with robust effects on cellular insulin action, in vivo insulin sensitivity, and overall
201 elevated cellular stress as well as impaired insulin action, increased glucose production and lipid d
203 unctionally link TUSC5 to GLUT4 trafficking, insulin action, insulin resistance, and PPARgamma action
204 istance, pioglitazone-induced improvement of insulin action is associated with an increase in muscle
208 mitochondrial performance, lipotoxicity, and insulin action is more complex than previously proposed.
210 le clinical observations have suggested that insulin action is not constant throughout the 24 hr cycl
211 that manifests with diet-induced obesity, as insulin action is preserved to protect fundamental energ
212 and browning of white fat, but intact liver insulin action is required for FGF21 to control hepatic
213 SP2), a protein previously unassociated with insulin action, is responsive to insulin stimulation.
217 egulate organismal metabolism by controlling insulin action, lipolysis, and mitochondrial respiration
219 ble to diet-induced glucose intolerance, and insulin action measured in isolated skeletal muscles rem
220 on and their relationship with biomarkers of insulin action, metabolomic profiling was carried out in
221 amps to show a bona fide circadian rhythm of insulin action; mice are most resistant to insulin durin
222 rosine phosphatase Shp1 negatively regulates insulin action on glucose homeostasis in liver and muscl
224 ay-selective insulin resistance by promoting insulin action on glucose metabolism but limiting hepati
226 n L6 myocytes and FAO hepatic cells improved insulin action on glucose uptake and glucose production,
227 perturbations are associated with failure of insulin action on GLUT4 traffic to the cell surface and
228 bility of forkhead box O6 (FoxO6) to mediate insulin action on hepatic gluconeogenesis and its contri
229 and growth-promoting IR signaling, prolongs insulin action on metabolism, and improves insulin sensi
231 human brain, we studied the impacts of brain insulin action on whole-body insulin sensitivity and the
233 etic variation at the TCF7L2 locus may alter insulin action or directly modify hepatic glucose metabo
235 Z-treated Gcgr(-/-) animals requires remnant insulin action originating from spared residual beta-cel
236 uvant therapy in diabetes only when residual insulin action persists, and ii) help devising future be
237 de in skeletal muscle linking CR to improved insulin action, primarily via modulation of PI3K signali
238 and pharmacology-based approaches to improve insulin action provide additional potential strategies t
241 ecule of insulin-like growth factor 1 (IGF1)/insulin actions, regulates Runx2 activity and expression
246 issue lipolysis, and impaired adipose tissue insulin action results in unrestrained lipolysis and lip
250 le for the renal nerves in the regulation of insulin action specifically at the level of the liver an
252 retion along with the established effects on insulin action suggest potential for HN and its analogs
253 everse the effects of maternal WSD on muscle insulin action, suggesting earlier interventions may be
254 at this translates into increased whole-body insulin action, suggesting that insulin action in rested
255 larger improvements in systemic and hepatic insulin action, systemic dyslipidemia, and reduction of
257 g reciprocity between SkM AMPK signaling and insulin action that manifests with diet-induced obesity,
258 itioning of RTKs in target cells for EGF and insulin action, the temporal extent of signaling, attenu
259 In addition to identifying a novel mode of insulin action, these data raise the possibility of deve
260 d IRS-1 phosphorylation by p70S6K1 attenuate insulin action through a negative feedback pathway.
261 reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fu
262 alpha-mediated hypoxic signaling and hepatic insulin action through Irs2 induction, which can be co-o
264 r, these results represent a novel branch of insulin action through the HNRNPK-miR-7 axis and highlig
265 benefit to enhance mitochondrial quality and insulin action to ameliorate complications associated wi
267 However, despite normalizing indices of insulin action to levels seen in the lean control (non-E
268 sma insulin response to offset the defect in insulin action to maintain normal glucose tolerance.
270 ined the effects of pericentrin depletion on insulin action using 3T3-L1 adipocytes as a model system
275 ; activation of glucokinase was restored and insulin action was improved, stimulating muscle glucose
277 in sensitivity compared with sedentary mice, insulin action was not affected by AraC administration.
282 on, hepatic fatty acid oxidation and hepatic insulin action were assessed in vitro using primary hepa
287 Reduced oxygen consumption and impaired insulin action were recapitulated in Parkin-null myotube
288 therefore propose a new model for CLASP2 in insulin action, where CLASP2 directs the delivery of GLU
290 h targeting the extramyocellular barriers to insulin action, which are critical to the pathogenesis o
291 ue (AT) inflammation contributes to impaired insulin action, which is a major cause of type 2 diabete
292 In summary, overfeeding impairs hypothalamic insulin action, which may contribute to unrestrained lip
293 r integrin signaling in facilitating hepatic insulin action while promoting lipid accumulation in mic
294 ectin secretion but not adipsin secretion or insulin action, while in preadipocytes it impaired adipo
295 cose-stimulated insulin secretion (GSIS) and insulin action, wild-type (sod2(+/+)) and heterozygous k
296 s that disturbing the natural rhythmicity of insulin action will disrupt the rhythmic internal enviro
297 severely disrupted, it is not known whether insulin action will lock to the peak, nadir, or mean of
298 ruitment using contrast-enhanced ultrasound, insulin action with euglycaemic hyperinsulinaemic clamp,
299 Lipid metabolism is important for health and insulin action, yet the fundamental process of regulatin